Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 15/20 | 0.66 |
| ▸ | SLC5A2 | P31639 | 12/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3675840 | 0.84 | SLC5A1 (0.53) | SLC5A1SLC5A2NPC1RAB9A | |
| SCHEMBL3676267 | 0.84 | SLC5A2 (0.59) | SLC5A1SLC5A2NPC1RAB9A | |
| SCHEMBL13254155 | 0.84 | SLC5A2 (0.54) | SLC5A1SLC5A2NPC1RAB9AHPGD | |
| Atigliflozin SCHEMBL13644156 | 0.81 | SLC5A2 (0.66) | SLC5A1SLC5A2NPC1RAB9A | |
| Atigliflozin SCHEMBL14981898 | 0.81 | SLC5A2 (0.66) | SLC5A1SLC5A2NPC1RAB9A | |
| Atigliflozin SCHEMBL19276485 | 0.81 | SLC5A2 (0.66) | SLC5A1SLC5A2NPC1RAB9A | |
| Atigliflozin SCHEMBL873867 | 0.81 | SLC5A2 (0.66) | SLC5A1SLC5A2NPC1RAB9A | |
| Atigliflozin SCHEMBL13641405 | 0.81 | SLC5A2 (0.66) | SLC5A1SLC5A2NPC1RAB9A | |
| Atigliflozin SCHEMBL874745 | 0.81 | SLC5A2 (0.66) | SLC5A1SLC5A2NPC1RAB9A | |
| Atigliflozin SCHEMBL15628877 | 0.81 | SLC5A2 (0.66) | SLC5A1SLC5A2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1964844-B1 | New thiophen glycoside derivatives, method for their manufacture, medicines containing these compounds and their application | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-09-01 | — | — | EP | disclosed |
| EP-1964844-B1 | New thiophen glycoside derivatives, method for their manufacture, medicines containing these compounds and their application | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-09-01 | — | — | EP | disclosed |
| EP-1964845-B1 | New thiophen glycoside derivatives, method for their manufacture, medicines containing these compounds and their application | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-08-11 | — | — | EP | disclosed |
| EP-1964845-B1 | New thiophen glycoside derivatives, method for their manufacture, medicines containing these compounds and their application | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-08-11 | — | — | EP | disclosed |
| EP-1967523-B1 | New thiophen glycoside derivatives, method for their manufacture, medicines containing these compounds and their application | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-08-11 | — | — | EP | disclosed |
| EP-1967523-B1 | New thiophen glycoside derivatives, method for their manufacture, medicines containing these compounds and their application | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-08-11 | — | — | EP | disclosed |
| US-7666848-B2 | such as 3-(4-Methoxy-phenyl)-1-[3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-thiophen-2-yl]-propan-1-one; for use as antidiabetics | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-02-23 | — | — | US | disclosed |
| US-7666848-B2 | such as 3-(4-Methoxy-phenyl)-1-[3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-thiophen-2-yl]-propan-1-one; for use as antidiabetics | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-02-23 | — | — | US | disclosed |
| US-7666848-B2 | such as 3-(4-Methoxy-phenyl)-1-[3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-thiophen-2-yl]-propan-1-one; for use as antidiabetics | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-02-23 | — | — | US | disclosed |
| WO-2009138195-A2 | USE OF THIOPHENE GLYCOSIDE DERIVATIVES FOR PRODUCING MEDICAMENTS FOR TREATMENT OF HYPERTENSION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-11-19 | — | — | WO | disclosed |
| EP-1967523-A1 | New thiophen glycoside derivatives, method for their manufacture, medicines containing these compounds and their application | Sanofi-Aventis Deutschland GmbH (DE) | 2008-09-10 | — | — | EP | disclosed |
| EP-1964845-A1 | New thiophen glycoside derivatives, method for their manufacture, medicines containing these compounds and their application | Sanofi-Aventis Deutschland GmbH (DE) | 2008-09-03 | — | — | EP | disclosed |
| EP-1964844-A1 | New thiophen glycoside derivatives, method for their manufacture, medicines containing these compounds and their application | Sanofi-Aventis Deutschland GmbH (DE) | 2008-09-03 | — | — | EP | disclosed |
| EP-1964844-A1 | New thiophen glycoside derivatives, method for their manufacture, medicines containing these compounds and their application | Sanofi-Aventis Deutschland GmbH (DE) | 2008-09-03 | — | — | EP | disclosed |
| EP-1964845-A1 | New thiophen glycoside derivatives, method for their manufacture, medicines containing these compounds and their application | Sanofi-Aventis Deutschland GmbH (DE) | 2008-09-03 | — | — | EP | disclosed |
| US-20060293252-A1 | Novel Thiophene Glycoside Derivatives, Processes for The Preparation, Medicaments Comprising These Compounds, and The Use Thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-12-28 | — | — | US | disclosed |
| US-7101856-B2 | Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-09-05 | — | — | US | disclosed |
| EP-1523488-A1 | NOVEL THIOPHENYLGLYCOSIDE DERIVATIVES, METHODS FOR PRODUCTION THEREOF, MEDICAMENTS COMPRISING SAID COMPOUNDS AND USE THEREOF | Aventis Pharma Deutschland GmbH (DE) | 2005-04-20 | — | — | EP | disclosed |
| US-20040138143-A1 | Novel thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
| WO-2004007517-A1 | NOVEL THIOPHENYLGLYCOSIDE DERIVATIVES, METHODS FOR PRODUCTION THEREOF, MEDICAMENTS COMPRISING SAID COMPOUNDS AND USE THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138143-A1 | Novel thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof | SLC5A1, SLC5A2, UGGT1 | SLC5A1 1/4885SLC5A2 2/4885NPC1 1257/4885 |
| US-20060293252-A1 | Novel Thiophene Glycoside Derivatives, Processes for The Preparation, Medicaments Comprising These Compounds, and The Use Thereof | SLC5A2, SLC5A1, DPP4 | SLC5A1 2/4885SLC5A2 1/4885NPC1 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.